Can we develop biomarkers that predict response of cancer patients to immunotherapy?

Author： Bonavida B.   Huerta-Yepez S.   Goodglick L.   Mizutani Y.   Miki T.  

Publisher： Informa Healthcare

ISSN： 1366-5804

Source： Biomarkers, Vol.10, Iss.1, 2005-11, pp. : 69-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Surrogate markers of response to cancer immunotherapy

By Morse M.A.   Clay T.M.   Hobeika A.C.   Mosca P.J.   Lyerly H.K.  

Expert Opinion on Biological Therapy, Vol. 1, Iss. 2, 2001-03 ,pp. : 153-158

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy and immunoprevention of cancer: where do we stand?

By Cavallo Federica   Curcio Claudia   Forni Guido  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 5, 2005-05 ,pp. : 717-726

Informa Healthcare

Access to resources Recommend Favorite

Natural killer: can they be useful as adoptive immunotherapy for cancer?

By Arai Sally   Klingemann Hans-G  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 2, 2005-02 ,pp. : 163-172

Informa Healthcare

Access to resources Recommend Favorite

How can Proteomics Reach Cancer Biomarkers?

By  

Current Proteomics, Vol. 10, Iss. 2, 2013-07 ,pp. : 136-149

Bentham Science Publishers

Access to resources Recommend Favorite

Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

By Lü Chen   Williams Andrew K   Chalasani Venu   Martínez Carlos H   Chin Joseph  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 1, 2011-01 ,pp. : 99-108

Informa Healthcare

Access to resources Recommend Favorite